Dominic Eisinger, Ph.D., Director

Dr. Dominic Eisinger serves on the Board of BioFactura as representative of a key strategic investor for the
series B and C financing, the University of Vermont Health Network (UVMHN) Ventures LLC. where he serves as
Vice Chair of the venture capital committee and is a UVMHN board member. In addition to his board role at
BioFactura, Dr. Eisinger leads global sales, marketing, new product development, and partnership strategies at
Myriad RBM, a CRO dedicated to biomarker testing for drug development clinical trials. He is the company’s lead
scientific speaker on pharmacodynamic protein biomarker research in oncology, inflammation, cardiovascular,
kidney, and autoimmune disease therapies. He has past experiencing cloning, expressing, amplifying, and
selecting high producing recombinant monoclonal antibodies from mammalian expression systems.

Dominic’s commercial success is grounded in his experiences as an entrepreneur. He co-founded, raised capital,
and built Multiplex Biosciences, a multiplex immunoassay development, validation, and manufacturing services
company, which was acquired by RBM. Dominic earned a Bachelor of Science from Cornell University and his
PhD from the University of Vermont, and later served as a Postdoctoral Research Fellow at Dartmouth Medical
School. Considered an international expert on multiplex immunoassays, his work appears in numerous peer-
reviewed publications and patented technologies.